DOCSLIB.ORG

Preliminary Results with the Nitric Oxide Donor Linsidomine Cholalhydrate in the Tratment of Human Erectile Dysfunction

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Preliminary Results with the Nitric Oxide Donor Linsidomine Cholalhydrate in the Tratment of Human Erectile Dysfunction The Journal of UROLOGY Editor John T. Grayhack 1120 North Charles Street Baltimore, Maryland 21201 Associate Editor Associate Editor Terry D. Allen Jay Y. Gillenwater Dallas, Texas Charlottesville,Virginia Section Editor Section Editor Stuart S. Howards Patrick C. Walsh Charlottesville, Virginia Baltimore, Maryland EDITORIAL BOARD Mid-Atlantic New England New York North Central A. Barry Belman Bernard Lytton Michael J. Droller Joseph W. Segura Washington, D. C. New Haven, Connecticut New York, New York Rochester, Minnesota Northeastern South Central Southeastern Western Abraham Τ. K. Cockett Robert E. Donohue Floyd A. Fried Duncan E. Govan Rochester, New York Denver, Colorado Chapel Hill, North Carolina Stanford, California BOARD OF CONSULTANTS Jonathan Epstein Howard M. Pollack Baltimore, Maryland Cheltenham, Pennsylvania Allyn W. Kimball William U. Shipley Baltimore, Maryland Boston, Massachusetts William M. Murphy Ronald R. Townsend Memphis, Tennessee Denver, Colorado Ryoichi Oyasu Colin White Chicago, Illinois New Haven, Connecticut Charles Y. C. Pak Alan Yagoda Dallas, Texas New York, New York FORMER EDITORS Hugh H. Young J. A. Campbell Colston Hugh J. Jewett William W. Scott Herbert Brendler 1917-1945 1945-1966 1966-1977 1977-1983 1983-1985 The Journal of Urology (ISSN 0022-5347) is the Official Journal of the American Urologicai Association, Inc., and is published monthly by Williams & Wilkins, 428 East Preston Street, Baltimore, MD 21202. Second class postage paid at Baltimore, MD, and at additional mailing offices. Subscription rates individual $193.00 ($258.00 foreign); institutions $215.00 ($280.00 foreign); in-training $95.00 ($160.00 foreign); single copy $23.00 ($28.00 foreign). Subscription prices subject to change. The GST number for Canadian subscribers is 123394371. To order call 1-800-638-6423 from anywhere in the U.S.; in Maryland call 1-800-638-4007. POSTMASTER: Send address changes to The Journal of Urology, 428 East Preston Street, Baltimore, MD 21202. Indexed by Current Contents, Index Medicus, and Excerpta Medica. Copyright© 1992 by American Urologicai Association, Inc. A4 The Journal of UROLOGY CLINICAL UROLOGY Review Article Use of Alloplastic Biomaterials in Bladder Substitution. M. J. Gleeson and D. P. Griffith 1377 Original Articles Renal Colic in Pregnancy. L. Stothers and L. M. Lee 1383 Therapeutic Use of Ganciclovir for Invasive Cytomegalovirus Infection in Cadaveric Renal Allograft Recipi­ ents. M. L. Jordan, R. L. Hrebinko, Jr., J. S. Dummer, D. P. Hickey, R. Shapiro, C. A. Vivas, R. L. Simmons, Τ. E. Starzl and T. R. Hakala 1388 Intraoperative Sonography of Renal Tumors. F. F. Marshall, S. S. Holdford and U. M. Hamper 1393 Clean Intermittent Catheterization and Urinary Diversion in Management of Renal Transplant Recipients With Lower Urinary Tract Dysfunction. /. S. Gill, J. M. Hayes, Ε. E. Hodge and A. C. Novick 1397 Complications of Radical Cystectomy and Urinary Diversion: Retrospective Review of 675 Cases in 2 Decades. H. A. Frazier, J. E. Robertson and D. F. Paulson 1401 Tamm-Horsfall Protein as Marker in Interstitial Cystitis. A. R. Stone, P. Vogelsang, C. H. Miller and J. P. MacDermott 1406 Idiopathic Reduced Bladder Storage Versus Interstitial Cystitis. S. A. Awad, S. MacDiarmid, J. B. Gajewski and R. Gupta 1409 Treated History of Noninvasive Grade 1 Transitional Cell Carcinoma. G. R. Ρ rout, Jr., B. A. Barton, P. P. Griffin and G. H. Friedell for National Bladder Cancer Group (Editorial Comment by Ε. M. Messing) . 1413 Prognostic Significance of Mucosal Aneuploidy in Stage Ta/Tl, Grade 3 Carcinoma of Bladder. U. Norming, B. Tribukait, C. R. Nyman, B. Nilsson and N. Wang (Editorial Comments by Ε. M. Messing, R. W. deVere White and M. J. Droller) 1420 Value of Immediate or Early Catheterization of Traumatized Posterior Urethra. S. Herschorn, A. Thijssen and S. B. Radomski 1428 Penile Extensibility: To What is it Related? P. Moreira de Goes, E. Wespes and C. Schulman 1432 Vascular Impotence: Focal or Diffuse Penile Disease. E. Wespes, P. Moreira de Goes and C. Schulman .. 1435 Preliminary Results With Nitric Oxide Donor Linsidomine Chlorhydrate in Treatment of Human Erectile Dysfunction. C. G. Stief, F. Holmquist, M. Djamilian, H. Krah, K.-E. Andersson and U. Jonas 1437 Volume-Dependent Intracavernous Hemodilution During Pharmacologically Induced Penile Erections. Q. H. Siraj, A. J. W. Hilson, J. Bomanji and M. Ahmed 1441 Early Experience With Controlled Girth and Length Expanding Cylinder of American Medical Systems Ultrex Penile Prosthesis. D. K. Montague and M. M. Lakin 1444 Varicocele Treatment: Prospective Randomized Trial of 3 Methods. J. Sayfan, Y. Soffer and R. Orda .... 1447 Test for Identification of Relevant Sympathetic Nerve Fibers During Nerve Sparing Retroperitoneal Lymph - adenectomy. K.-P. Dieckmann, Η. Huland and A. J. Gross (Editorial Comment by Κ. T. McVary) . 1450 Pilot Study to Evaluate Impact of Policy of Adjuvant Chemotherapy for High Risk Stage 1 Malignant Teratoma on Overall Relapse Rate of Stage 1 Cancer Patients. R. T. D. Oliver, M. A. Raja, J. Ong and C. J. Gallagher (Editorial Comments by J. P. Richie and J. P. Donohue) 1453 Quantitative Measurement of Prostatic Blood Flow and Blood Volume by Positron Emission Tomogra­ phy. T. Inaba 1457 Characterization of Nonbacterial Prostatitis: Search for Etiology. L. M. D. Shortliffe, R. G. Sellers and J. Schachter 1461 Randomized, Placebo-Controlled Multicenter Study of Efficacy and Safety of Terazosin in Treatment of Benign Prostatic Hyperplasia. H. Lepor, S. Auerbach, A. Puras-Baez, P. Narayan, M. Soloway, F. Lowe, T. Moon, G. Leifer and P. Madsen 1467 Transurethral Surgery Using Intravesical Bupivacaine and Intravenous Sedation. R. D. Matthews, J. F. Nolan, J. A. Libby-Straw and J. P. Sands, Jr 1475 Urologicai Neurology and Urodynamics Ambulatory Monitoring of Bladder Pressure in Low Compliance Neurogenic Bladder Dysfunction. R. J. Webb, C. J. Griffiths, P. D. Ramsden and D. E. Neal 1477 Pediatric Articles Quantitative Histological Analysis of Dilated Ureter of Childhood. B. R. Lee, A. W. Partin, J. I. Epstein, D. M. Quinlan, J. A. Gosling and J. P. Gearhart 1482 Prenatal Diagnosis of Megacystis-Megaureter Association. J. Mandell, R. L. Lebowitz, C. A. Peters, J. A. Estroff, A. B. Retik and B. R. Benacerraf 1487 Contents continued on page A10 A6 Contents continued from page A6 Endopyelotomy Associated Ureteral Necrosis: Complete Ureteral Replacement Using Boari Flap. R. S. Sutherland, R. R. Pfister and M. A. Koyle 1490 Influence of Preoperative Bladder Capacity and Compliance on Outcome of Artificial Sphincter Implantation in Patients With Neurogenic Sphincter Incompetence. F. I. P. de Badiola, D. Castro-Diaz, C. Hart- Austin and R. Gonzalez 1493 Adventitious Knots in Urethral Catheters: Report of 5 Cases. H. Foster, M. Ritchey and D. Bbom 1496 Radiographic and Serologic Correlates of Azotemia in Patients With Posterior Urethral Valves. P. A. Merguerian, G. A. McLorie, Β. M. Churchill, P. H. McKenna and A. E. Khoury 1499 Urethral Stricture in Children: Treatment by Urethroplasty With Bladder Mucosa Graft. G. Monfort, D. Bretheau, V. Di Benedetto and R. Bankole 1504 Onlay Island Flap Urethroplasty: Variation on Theme. J. P. Gearhart and R. N. Borland 1507 Penoscrotal Transposition With Hypospadias: 1-Stage Repair. S. Perovic and V. Vukadinovic 1510 Intraoperative Spermatic Venography During Varicocele Surgery in Adolescents. R. R. Hart, Η G. Rushton and A. B. Belman 1514 Case Reports Endocytosis of Calcium Oxalate Crystals and Proliferation of Renal Tubular Epithelial Cells in Patient With Type 1 Primary Hyperoxaluria. J. C. Lieske, Β. H. Spargo and F. G. Toback 1517 Arteriovenous Fistula Complicating Endopyelotomy. E. S. Maiden, D. Picus and R. V. dayman 1520 Control of Massive Hematuria in Idiopathic Hemorrhagic Cystitis After Administration of Conjugated Estrogen. J. M. Rodriguez Luna, J. L. Teruel, J. Vallejo, F. J. Burgos, F. Lovaco and T. Mayayo 1524 Leiomyoma of Female Urethra: Case Report and Review. C. Cheng, F. M.-M. Lai and P. S. F. Chan 1526 Management of Injuries to Urethra, Bladder or Vagina Encountered During Difficult Placement of Artificial Urinary Sphincter in Female Patient. J. A. Salisz and A. C. Diokno 1528 Use of Polytetrafluoroethylene Tube Graft as Circumferential Neotunica During Placement of Penile Prosthesis. A. D. Seftel, R. D. Oates and L Goldstein 1531 Epididymo-Orchitis Developing as Late Manifestation of Intravesical Bacillus Calmette-Guerin Therapy and Masquerading as Primary Testicular Malignancy: Report of 2 Cases. T. Truelson, Κ. I. Wishnow and D.E.Johnson 1534 Prostatic Abscess Due to Candida Tropicalis in Nonacquired Immunodeficiency Syndrome Patient. S. Yu andJ.Provet 1536 Idiopathic Resistance to Luteinizing Hormone-Releasing Hormone Analogue in Patient With Prostatic Carcinoma. J. L. Jorion 1539 Recurrent Prostate Cancer Despite Undetectable Prostate Specific Antigen. Τ. K. Takayama, J. N. Krieger, L. D. True and P. Η Lange 1541 Papillary Adenocarcinoma in Seminal Vesicle Cyst Associated With Ipsilateral Renal Agenesis. Y. Okada, H. Tanaka, H. Takeuchi and O. Yoshida 1543 Special Communications Hard Measures of Subjective Outcomes: Validating Symptom Indexes in Urology. M. P. O'Leary, M. J. Barry and F. J. Fowler, Jr 1546 American Urologicai Association Symptom Index for Benign Prostatic Hyperplasia. M. J. Barry, F. J. Fowler, Jr., M. P. O'Leary, R. C. Bruskewitz, Η L. Holtgrewe, W. K. Mebust, Α. Τ. Κ Cockett and Measurement Committee of American Urologicai Association
Load more

Recommended publications
  • Use of Gasotransmitters for the Controlled Release of Polymer
    Journal of Controlled Release 279 (2018) 157–170 Contents lists available at ScienceDirect Journal of Controlled Release journal homepage: www.elsevier.com/locate/jconrel Review article Use of gasotransmitters for the controlled release of polymer-based nitric T oxide carriers in medical applications ⁎ ⁎⁎ Chungmo Yanga,1, Soohyun Jeonga,1, Seul Kub, Kangwon Leea,c, , Min Hee Parka, a Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Republic of Korea b School of Medicine, Stanford University, 291 Campus Drive, Stanford, CA 94305, USA c Advanced Institutes of Convergence Technology, Gyeonggi-do 16229, Republic of Korea ARTICLE INFO ABSTRACT Keywords: Nitric Oxide (NO) is a small molecule gasotransmitter synthesized by nitric oxide synthase in almost all types of Nitric oxide mammalian cells. NO is synthesized by NO synthase by conversion of L-arginine to L-citrulline in the human Polymeric carrier body. NO then stimulates soluble guanylate cyclase, from which various physiological functions are mediated in fi Hydrogen sul de a concentration-dependent manner. High concentrations of NO induce apoptosis or antibacterial responses Carbon monoxide whereas low NO circulation leads to angiogenesis. The bidirectional effect of NO has attracted considerable Crosstalk of gasotransmitters attention, and efforts to deliver NO in a controlled manner, especially through polymeric carriers, has been the Stimuli-responsive topic of much research. This naturally produced signaling molecule has stood out as a potentially more potent therapeutic agent compared to exogenously synthesized drugs. In this review, we will focus on past efforts of using the controlled release of NO via polymer-based materials to derive specific therapeutic results.
    [Show full text]
  • Tolerance and Resistance to Organic Nitrates in Human Blood Vessels
    \ö-\2- Tolerance and Resistance to Organic Nitrates in Human Blood Vessels Peter Radford Sage MBBS, FRACP Thesis submit.ted for the degree of Doctor of Philosuphy Department of Medicine University of Adelaide and Cardiology Unit The Queen Elizabeth Hospital I Table of Gontents Summary vii Declaration x Acknowledgments xi Abbreviations xil Publications xtil. l.INTRODUCTION l.L Historical Perspective I i.2 Chemical Structure and Available Preparations I 1.3 Cellular/biochemical mechanism of action 2 1.3.1 What is the pharmacologically active moiety? 3 1.3.2 How i.s the active moiety formed? i 4 1.3.3 Which enzyme system(s) is involved in nitrate bioconversi<¡n? 5 1.3.4 What is the role of sulphydryl groups in nitrate action? 9 1.3.5 Cellular mechanism of action after release of the active moiety 11 1.4 Pharmacokinetics t2 1.5 Pharmacological Effects r5 1.5.1 Vascular effects 15 l.5.2Platelet Effects t7 1.5.3 Myocardial effects 18 1.6 Clinical Efhcacy 18 1.6.1 Stable angina pectoris 18 1.6.2 Unstable angina pectoris 2t 1.6.3 Acute myocardial infarction 2l 1.6.4 Congestive Heart Failure 23 ll 1.6.5 Other 24 1.7 Relationship with the endothelium and EDRF 24 1.7.1 EDRF and the endothelium 24 1.7.2 Nitrate-endothelium interactions 2l 1.8 Factors limiting nitrate efficacy' Nitrate tolerance 28 1.8.1 Historical notes 28 1.8.2 Clinical evidence for nitrate tolerance 29 1.8.3 True/cellular nitrate tolerance 31 1.8.3.1 Previous studies 31 | .8.3.2 Postulated mechanisms of true/cellular tolerance JJ 1.8.3.2.1 The "sulphydryl depletion" hypothesis JJ 1.8.3.2.2 Desensitization of guanylate cyclase 35 1 8.i.?..3 Impaired nitrate bioconversion 36 1.8.3.2.4'Ihe "superoxide hypothesis" 38 I.8.3.2.5 Other possible mechanisms 42 1.8.4 Pseudotolerance ; 42 1.8.4.
    [Show full text]
  • Current Status of Local Penile Therapy
    International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Current status of local penile therapy F Montorsi1*, A Salonia1, M Zanoni1, P Pompa1, A Cestari1, G Guazzoni1, L Barbieri1 and P Rigatti1 1Department of Urology, University Vita e Salute – San Raffaele, Milan, Italy Guidelines for management of patients with erectile dysfunction indicate that intraurethral and intracavernosal injection therapies represent the second-line treatment available. Efficacy of intracavernosal injections seems superior to that of the intraurethral delivery of drugs, and this may explain the current larger diffusion of the former modality. Safety of these two therapeutic options is well established; however, the attrition rate with these approaches is significant and most patients eventually drop out of treatment. Newer agents with better efficacy-safety profiles and using user-friendly devices for drug administration may potentially increase the long-term satisfaction rate achieved with these therapies. Topical therapy has the potential to become a first- line treatment for erectile dysfunction because it acts locally and is easy to use. At this time, however, the crossing of the barrier caused by the penile skin and tunica albuginea has limited the efficacy of the drugs used. International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81. DOI: 10.1038= sj=ijir=3900808 Keywords: erectile dysfunction; local penile therapy; topical therapy; alprostadil Introduction second patient category might be represented by those requesting a fast response, which cannot be obtained by sildenafil; however, sublingual apomor- Management of patients with erectile dysfunction phine is characterized by a fast onset of action and has been recently grouped into three different may represent an effective solution for these 1 levels.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Regulation of Extracellular Arginine Levels in the Hippocampus in Vivo
    Regulation of Extracellular Arginine Levels in the Hippocampus In Vivo by Joanne Watts B.Sc. (Hons) r Thesis submitted for the degree of Doctor of Philosophy in the Faculty of Science, University of London The School of Pharmacy University of London ProQuest Number: 10105113 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10105113 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Nitric oxide (NO) has emerged as an ubiquitous signaling molecule in the central nervous system (CNS). NO is synthesised from molecular oxygen and the amino acid L-arginine (L- ARG) by the enzyme NO synthase (NOS), and the availability of L-ARG has been implicated as the limiting factor for NOS activity. Previous studies have indicated that L- ARG is localised in astrocytes in vitro and that the in vitro activation of non-N-methyl-D- aspartate (NMDA) receptors, as well as the presence of peroxynitrite (ONOO ), led to the release of L-ARG. Microdialysis was therefore used in this study to investigate whether this held true in vivo.
    [Show full text]
  • A New Look at the Etiology of Interstitial Cystitis/Bladder Pain Syndrome: Extraordinary Cultivations
    International Urology and Nephrology (2019) 51:1961–1967 https://doi.org/10.1007/s11255-019-02248-5 UROLOGY - ORIGINAL PAPER A new look at the etiology of interstitial cystitis/bladder pain syndrome: extraordinary cultivations Tahsin Batuhan Aydogan1 · Oznur Gurpinar2 · Ozgen Koseoglu Eser2 · Begum Aydogan Mathyk3 · Ali Ergen1 Received: 25 April 2019 / Accepted: 24 July 2019 / Published online: 30 July 2019 © Springer Nature B.V. 2019 Abstract Purpose So far, studies have not clearly identifed infectious agents as an etiological factor for interstitial cystitis (IC). Spe- cifc microbiological diagnosis for detecting the pathogen with higher sensitivity in IC may decrease the treatment costs and increase psychosocial health of the patients. Methods A prospective clinical study was performed in 26 IC patients and 20 controls between April and September 2017. All participants were asked to give mid-stream urine sample for routine urine cultures. Followed by the negative results, symptomatic 26 patients were evaluated for L-form pathogen existence by extraordinary cultivation methods. Biopsy sam- ples were taken from 19 patients with ulcerative lesions in the bladder while collecting sterile urine samples from all 26 patients. PG broth, 5% sheep blood agar, EMB, Sabouraud’s dextrose, LEM, and GYPA were used. Followed by the 1st day inoculations, all inoculated PG broths were subcultured into the same solid media at the 2nd and 10th days in case of any growth after incubation of 24 h under 35–37 °C. The “O’Leary Sant Symptom and Problem Index” score forms were used to evaluate response to the appropriate treatment for those patients with documented pathogens.
    [Show full text]
  • Interstitial Cystitis/Painful Bladder Syndrome
    What I need to know about Interstitial Cystitis/Painful Bladder Syndrome U.S. Department of Health and Human Services National Kidney and Urologic Diseases NATIONAL INSTITUTES OF HEALTH Information Clearinghouse What I need to know about Interstitial Cystitis/Painful Bladder Syndrome U.S. Department of Health and Human Services National Kidney and Urologic Diseases NATIONAL INSTITUTES OF HEALTH Information Clearinghouse Contents What is interstitial cystitis/painful bladder syndrome (IC/PBS)? ............................................... 1 What are the signs of a bladder problem? ............ 2 What causes bladder problems? ............................ 3 Who gets IC/PBS? ................................................... 4 What tests will my doctor use for diagnosis of IC/PBS? ............................................................... 5 What treatments can help IC/PBS? ....................... 7 Points to Remember ............................................. 14 Hope through Research........................................ 15 Pronunciation Guide ............................................. 16 For More Information .......................................... 17 Acknowledgments ................................................. 18 What is interstitial cystitis/painful bladder syndrome (IC/PBS)? Interstitial cystitis*/painful bladder syndrome (IC/PBS) is one of several conditions that causes bladder pain and a need to urinate frequently and urgently. Some doctors have started using the term bladder pain syndrome (BPS) to describe this condition. Your bladder is a balloon-shaped organ where your body holds urine. When you have a bladder problem, you may notice certain signs or symptoms. *See page 16 for tips on how to say the words in bold type. 1 What are the signs of a bladder problem? Signs of bladder problems include ● Urgency. The feeling that you need to go right now! Urgency is normal if you haven’t been near a bathroom for a few hours or if you have been drinking a lot of fluids.
    [Show full text]
  • Symptoms of Overactive Bladder and Interstitial Cystitis – How Different?
    183 Homma Y1, Tanaka M1, Niimi A1 1. Japan Red Cross Medical Centre SYMPTOMS OF OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS – HOW DIFFERENT? Hypothesis / aims of study Overactive bladder (OAB) is a symptom syndrome of urgency, frequency or urgency incontinence [1]. Interstitial cystitis (IC) is a bladder disease with a symptom syndrome of urgency, frequency, or bladder pain. Difference in symptoms of these confusable disorders is to be examined. Study design, materials and methods Female patients with OAB or IC and asymptomatic controls were recruited for the study. Diagnosis of OAB is based on 1) OAB symptom score [2] larger than 5 and/or urgency incontinence, and 2) exclusion of stress urinary incontinence and other obvious diseases. IC was diagnosed by 1) O’Leary & Sant’s symptom score [3] larger than 7 and/or bladder pain, 2) exclusion of other obvious diseases, and 3) Hunner’s ulcer or bladder bleeding at hydrodistension under anesthesia. The subjects recorded, in 3-day bladder diary, time voided, voided volume and intensity (0: none, 1: slightly, 2: moderately, 3: a lot) of 6 sensations or symptoms (urge to void, fear of leakage, amount of leakage, bladder discomfort, bladder pain and feeling of incomplete emptying) for each micturition. Additionally the urge questionnaire of 5 questions addressing the conditions during the last week was administered: 1) Did you feel urge to void that was not followed by voiding? (Response: yes, no), 2) Did you feel strong urge to void? (yes, no), 3) In case of yes in question 2, did you feel strong urge to void suddenly? (yes, no), 4) What happened or might happen, if you held strong urge to void for a long time, 1 hour for example ? (Response: leak urine, feel discomfort and/or pain, both), 5) In case of discomfort and/or pain in question 4, could you tell these 2 sensations apart? (yes, no).
    [Show full text]
  • SUMMARY of PRODUCT CHARACTERISTICS 1. NAME of the MEDICINAL PRODUCT XATRAL 2.5 Mg Film-Coated Tablets. XATRAL SR 5 Mg Sustained
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT XATRAL 2.5 mg film-coated tablets. XATRAL SR 5 mg sustained-release tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each Xatral 2.5 mg tablet contains 2.5mg alfuzosin hydrochloride. Each Xatral SR 5 mg tablet contains 5mg alfuzosin hydrochloride. 3. PHARMACEUTICAL FORM Xatral 2.5 mg is a white round film coated tablet for oral administration. Xatral SR 5 mg is a pale yellow biconvex film coated sustained release tablet for oral administration. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Xatral 2.5mg: Treatment of certain functional symptoms of benign prostatic hypertrophy, notably when surgery has to be delayed for whatever reason and during episodes of severe symptoms of adenoma, especially in elderly patients. Xatral SR 5 mg: Treatment of certain functional symptoms of benign prostatic hypertrophy, particularly if surgery has to be delayed for some reason. 4.2 Posology and method of administration Oral use Xatral SR 5mg tablet must be swallowed whole with a glass of water (see Section 4.4). The first dose of Xatral SR 5mg or Xatral 2.5 mg tablets should be given just before bedtime. Adults: Xatral 2.5mg: The recommended dosage is one tablet Xatral® 2.5mg three times daily. The dose may be increased to a maximum of 4 tablets (10mg) per day depending on the clinical response. ® Xatral SR 5mg: The usual dose is one Xatral SR 5 mg tablet morning and evening. Elderly patients (over 65 years) or patients treated for hypertension: Xatral 2.5mg: as a routine precaution, it is recommended that treatment be started with one Xatral 2.5 mg tablet morning and evening and that the dosage then be increased on the basis of the patient's individual response, without exceeding the maximum dosage of 4 Xatral 2.5 mg tablets daily.
    [Show full text]
  • Interstitial Cystitis? You May Have Interstitial Cystitis If Any of the Following Occur: Interstitial Cystitis • You Have to Urinate Often Or Urgently
    the bladder wall. An autoimmune response (when antibodies are made that act against a part of the body such as in rheumatoid arthritis) may also be the cause in some people. How does my doctor know I have interstitial cystitis? You may have interstitial cystitis if any of the following occur: Interstitial Cystitis • You have to urinate often or urgently. • You have persistent pelvic or bladder pain. A Guide for Women • A doctor finds bladder wall inflammation, pinpoint bleed- 1. What is interstitial cystitis? ing or ulcers during an exam with a special telescope 2. What causes interstitial cystitis? (called a cystoscope) used to look inside your bladder. 3. How does my doctor know I have interstitial cystitis? • Your doctor has ruled out other diseases such as urinary 4. How is interstitial cystitis treated? tract infections, vaginal infections, bladder cancer, and sexually transmitted diseases that may mimic some of the 5. Other Treatment Options symptoms of interstitial cystitis. 6. Where can I get more information about interstitial How is interstitial cystitis treated? cystitis? Because the causes of IC are unknown, current treatments are aimed at relieving symptoms. One or a combination of treat- ments helps most people for variable periods. As researchers What is interstitial cystitis? learn more about IC the list of potential treatments will change, Interstitial cystitis (IC) is a term used to describe the condition so patients should discuss their options with a doctor. Most peo- of bladder pain or discomfort with a frequent and often urgent ple feel better after trying one or more of the following treat- need to pass urine.
    [Show full text]
  • Associated Diseases in Interstitial Cystitis/Bladder Pain Syndrome
    Associated diseases in interstitial cystitis/bladder pain syndrome Joop P. van de Merwe [email protected] Associated diseases in IC/BPS patients Table 1. Examples of associated disorders diagnosed in IC/BPS patients in comparison with Associated diseases are diseases that occur more often the general population 2,5,6 together in the same person than by chance. Associated diseases for IC/BPS (interstitial cystitis/bladder pain diagnosis prevalence (%) syndrome) include allergy, fibromyalgia, irritable bowel IC/BPS general syndrome, Crohn's disease, ulcerative colitis, systemic lupus population erythematosus, rheumatoid arthritis and Sjögren's syndrome allergy 40.6 22.5 (table 1). irritable bowel syndrome 25.4 2.9 sensitive skin 22.6 10.6 Allergy vulvodynia 10.9 15.0 An allergy occurs when a person's immune system causes an fibromyalgia 12.8 3.2 adverse reaction to substances in the environment that are chronic fatigue syndrome 7.7 8.5 harmless to most other people. These substances (so-called migraine 18.8 18.0 allergens) are found in dust mites, pets, pollen, insects, ticks, asthma 9.2 6.1 15 moulds, foods and many medications. Adverse reactions Crohn’s disease/ulcerative colitis 7.3 0.07 without involvement of the immune system are called rheumatoid arthritis 4-13 1.0 intolerance. Intolerance mainly occurs to food ingredients and systemic lupus erythematosus 1.7 0.05 drugs. Sjögren’s syndrome 8.0 0.5 People experience different symptoms, depending on the allergen, the individual's immune system, previous contact with the same allergen and where it enters the body.
    [Show full text]
  • NCX-4040, a Unique Nitric Oxide Donor, Induces Reversal of Drug-Resistance in Both ABCB1- and ABCG2-Expressing Multidrug Human Cancer Cells
    cancers Article NCX-4040, a Unique Nitric Oxide Donor, Induces Reversal of Drug-Resistance in Both ABCB1- and ABCG2-Expressing Multidrug Human Cancer Cells Birandra K. Sinha 1,*, Lalith Perera 2 and Ronald E. Cannon 1 1 Laboratory of Toxicology and Toxicokinetic, National Cancer Institute at National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA; [email protected] 2 Laboratory of Genome Integrity and Structural Biology, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-984287-3382 Simple Summary: Development of resistance to chemotherapeutics during the treatment of human cancers is a serious problem in the clinic, resulting in a poor treatment outcome and survival. It is believed that overexpression of ABC efflux proteins (e.g., P-gp/ABCB1, BCRP/ABCG2 and MRP/ABCC1) on the tumor cell membrane is one of the main mechanisms for this clinical resistance. Our recent studies indicate that nitric oxide (NO), inhibits ATPase functions of ABC transporters, resulting in reversal of resistance to various anticancer drugs. In this study we have found that nitric oxide and/or active metabolite (s) generated from NCX4040, a nitric oxide donor, inhibited ABC transporter activities by inhibiting their ATPase functions, causing reversal of both adriamycin and topotecan resistance in human MDR tumor cells. We also found that nitric oxide and/or metabolites of NCX4040 significantly enhanced drug accumulations in MDR tumor cells. These Citation: Sinha, B.K.; Perera, L.; studies strongly suggest that tumor specific nitric oxide donors that deliver high amounts of nitric Cannon, R.E.
    [Show full text]